Bone loss drugs linked to lower ovarian cancer rates

0

Bone loss drugs linked to lower ovarian cancer rates: Drugs used to prevent bone loss may help reduce risk of ovarian cancer according to study by The University of Queensland.

UQ researchers compared the medications taken by more than 50,000 women over the age of 50, using anonymized medical records from 2004 to 2013, to analyze the differences between those with prostate cancer. ovary and those that don’t.

Medicines used to prevent bone loss may help reduce the risk of ovarian cancer according to a study from the University of Queensland.

UQ researchers compared the medications taken by more than 50,000 women over the age of 50, using anonymized medical records from 2004 to 2013, to analyze the differences between those with prostate cancer. ovary and those that don’t.
A female person with her hands on her lower abdomen, which is glowing
Picture: Adobe

Doctorate from the UQ School of Public Health Candidate Karen Tusley reported that women who used nitrogen-based bisphosphonates were less likely to develop ovarian cancer.

“Findings varied between ovarian cancer subtypes and included a 50% lower risk for endometrioid cancers and 16% lower risk for serous ovarian cancers,” Ms Tuesley said.

“We don’t yet know why these drugs can reduce the risk of ovarian cancer in women, but previous studies have shown that nitrogen-based bisphosphonates can stop the spread of the disease in cells cultured in the laboratory. .

“Ovarian cancer is the eighth most common cancer in Australian women with less than 50% of patients alive five years after diagnosis.”

In 2021, 1,720 cases of ovarian cancer were diagnosed, and 83% of them occurred in women over the age of 50, according to the Australian Institute of Health and Wellness.

Over 200,000 Australians are prescribed nitrogen-containing bisphosphonates each year, making it one of the most prescribed such drugs in the country.

The drugs prevent bone loss and help reduce fractures in patients with osteoporosis.

Supervisor Associate Professor Susan Jordan said this study is important because most of the known risk factors for ovarian cancer cannot be easily changed.

“Previous studies have shown that drugs used to treat other diseases can be helpful in preventing cancer, which prompted this investigation into bisphosphonates,” Dr. Jordan said.

“Further research is needed to understand why these drugs might affect ovarian cancer subtypes differently.

“We know that ovarian cancer subtypes look different under the microscope and have unique risk factors.

“However, it is important to examine each subtype separately to improve our knowledge and understanding of these cancers.

“This study may help inform drug choices for women with osteoporosis and suggest areas for further research to better understand how ovarian cancer develops.”

The article is published in the JNCI: Journal of the National Cancer Institute.

Hippocratic post
Latest articles by Hippocratic Post (see everything)
Share.

Comments are closed.